Ensysce Biosciences, Inc.
ENSC · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | $1,673 | $2,212 | $3,052 | $3,502 |
| Short-Term Investments | $0 | $0 | $0 | $0 |
| Receivables | $4 | $1,205 | $22 | $124 |
| Inventory | $0 | $0 | $0 | $0 |
| Other Curr. Assets | $1,251 | $1,865 | $1,327 | $1,718 |
| Total Curr. Assets | $2,928 | $5,282 | $4,401 | $5,345 |
| Property Plant & Equip (Net) | $124 | $0 | $0 | $0 |
| Goodwill | $0 | $0 | $0 | $0 |
| Intangibles | $0 | $0 | $0 | $0 |
| Long-Term Investments | $0 | $0 | $0 | $0 |
| Tax Assets | $0 | $0 | $0 | $0 |
| Other NC Assets | $128 | $293 | $211 | $253 |
| Total NC Assets | $251 | $293 | $211 | $253 |
| Other Assets | $0 | $0 | $0 | $0 |
| Total Assets | $3,179 | $5,574 | $4,612 | $5,597 |
| Liabilities | – | – | – | – |
| Payables | $463 | $1,043 | $615 | $1,357 |
| Short-Term Debt | $364 | $425 | $257 | $302 |
| Tax Payable | $0 | $0 | $0 | $0 |
| Deferred Revenue | $0 | $0 | $0 | $0 |
| Other Curr. Liab. | $1,477 | $1,046 | $888 | $548 |
| Total Curr. Liab. | $2,305 | $2,513 | $1,761 | $2,207 |
| LT Debt | $0 | $0 | $0 | $0 |
| Deferred Rev, NC | $0 | $0 | $0 | $0 |
| Deferred Tax Liab, NC | $0 | $0 | $0 | $0 |
| Other NC Liab. | $0 | $1 | $130 | $10 |
| Total NC Liab. | $0 | $1 | $130 | $10 |
| Other Liabilities | $0 | $0 | $0 | $0 |
| Cap. Leases | $0 | $0 | $0 | $0 |
| Total Liabilities | $2,305 | $2,514 | $1,891 | $2,217 |
| Equity | – | – | – | – |
| Pref Stock | $0 | $0 | $0 | $0 |
| Common Stock | $0 | $0 | $0 | $0 |
| Retained Earnings | -$136,952 | -$133,223 | -$131,490 | -$129,544 |
| AOCI | $0 | $0 | $0 | $0 |
| Other Equity | $138,155 | $136,612 | $134,539 | $133,253 |
| Total Equity | $1,203 | $3,389 | $3,049 | $3,708 |
| Supplemental Information | – | – | – | – |
| Minority Interest | -$329 | -$329 | -$328 | -$328 |
| Total Liab. & Tot. Equity | $3,179 | $5,574 | $4,612 | $5,597 |
| Net Debt | -$1,309 | -$1,787 | -$2,795 | -$3,200 |